• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Graphite Bio Inc. (Amendment)

    2/5/24 4:31:56 PM ET
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $GRPH alert in real time by email
    SC 13G/A 1 d710000dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    GRAPHITE BIO, INC.

    (Name of Issuer)

    Common Stock, Par Value $0.00001 Per Share

    (Title of Class of Securities)

    38870X104

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 38870X104    13G/A    Page 2 of 5 Pages

     

      1.    

      NAMES OF REPORTING PERSONS

     

      Matthew Porteus    

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.     

      SOLE VOTING POWER

     

      3,548,529 shares of Common Stock

       6.   

      SHARED VOTING POWER

     

      0

       7.   

      SOLE DISPOSITIVE POWER

     

      3,548,529 shares of Common Stock

       8.   

      SHARED DISPOSITIVE POWER

     

      0

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      3,548,529 shares of Common Stock (1)

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      6.1% (2)

    12.  

      TYPE OF REPORTING PERSON

     

      IN

     

    (1)

    Consists of (i) 3,528,529 shares of Common Stock held directly by Matthew Porteus and (ii) 20,000 shares of Common Stock issuable within 60 days after December 31, 2023 upon the exercise of options held directly by Matthew Porteus.

    (2)

    Percentage ownership is based on (i) 58,008,396 shares of Common Stock outstanding as of December 31, 2023 and (ii) 20,000 shares of Common Stock issuable within 60 days after December 31, 2023 upon the exercise of options held directly by Matthew Porteus, which have been added to the Common Stock reported as outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act.


    CUSIP No. 38870X104    13G/A    Page 3 of 5 Pages

     

    Item 1(a).

    Name of Issuer:

    Graphite Bio, Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    611 Gateway Boulevard, Suite 120

    South San Francisco, CA 94080

     

    Item 2(a).

    Name of Person Filing:

    Matthew Porteus

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    c/o Graphite Bio, Inc.

    611 Gateway Boulevard, Suite 120

    South San Francisco, CA 94080

     

    Item 2(c).

    Citizenship:

    United States

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock

     

    Item 2(e).

    CUSIP Number:

    38870X104

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)        ☐   Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

    (b)        ☐   Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

    (c)        ☐   Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

    (d)        ☐   Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a- 8).

    (e)        ☐   An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E);

    (f)        ☐   An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F);

    (g)        ☐   A parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G);

    (h)        ☐   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)        ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j)        ☐ Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).

    Not applicable.


    CUSIP No. 38870X104    13G/A    Page 4 of 5 Pages

     

     

    Item 4.

    Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)

    Amount beneficially owned: 3,548,529 shares of Common Stock which consists of (i) 3,528,529 shares of Common Stock held directly by Matthew Porteus and (ii) 20,000 shares of Common Stock issuable within 60 days after December 31, 2023 upon the exercise of options held directly by Matthew Porteus.

     

    (b)

    Percent of class: 6.1%

    The foregoing percentage is calculated based on (i) 58,008,396 shares of Common Stock outstanding as of December 31, 2023 and (ii) 20,000 shares of Common Stock issuable within 60 days after December 31, 2023 upon the exercise of options held directly by Matthew Porteus, which have been added to the Common Stock reported as outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act.

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote: 3,548,529

     

      (ii)

    Shared power to vote or to direct the vote: 0

     

      (iii)

    Sole power to dispose or to direct the disposition of: 3,548,529

     

      (iv)

    Shared power to dispose or to direct the disposition of: 0

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    Not applicable.


    CUSIP No. 38870X104    13G/A    Page 5 of 5 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 5, 2024

     

    /s/ Matthew Porteus

    Matthew Porteus
    Get the next $GRPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRPH

    DatePrice TargetRatingAnalyst
    2/23/2023$3.00 → $2.00Neutral → Underperform
    BofA Securities
    2/23/2023$3.00Overweight → Neutral
    Cantor Fitzgerald
    2/23/2023Outperform → Market Perform
    Cowen
    1/25/2023Buy → Neutral
    BTIG Research
    1/18/2023$7.00 → $3.00Buy → Neutral
    BofA Securities
    1/6/2023$11.00 → $2.00Outperform → Mkt Perform
    SVB Leerink
    1/6/2023$14.00 → $7.00Outperform → Market Perform
    BMO Capital Markets
    9/15/2022$12.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $GRPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Graphite Bio downgraded by BofA Securities with a new price target

      BofA Securities downgraded Graphite Bio from Neutral to Underperform and set a new price target of $2.00 from $3.00 previously

      2/23/23 8:58:13 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Graphite Bio from Overweight to Neutral and set a new price target of $3.00

      2/23/23 8:56:04 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio downgraded by Cowen

      Cowen downgraded Graphite Bio from Outperform to Market Perform

      2/23/23 6:14:16 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    $GRPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics

      Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger Graphite Bio, Inc. (NASDAQ:GRPH) ("Graphite" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Lenz Therapeutics, Inc. ("LENZ") pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.03 per share of Graphite's common stock, will be payable in cash to the stockholders of record as of March 18, 2024. The exact amount of the special dividend will be calculated afte

      3/8/24 5:00:00 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • LENZ Therapeutics and Graphite Bio Announce Merger Agreement

      - Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics' lead assets for the treatment of presbyopia - Combined company expected to have approximately $225 million of cash or cash equivalents at close, including $53.5 million from a concurrent PIPE financing - Companies to host joint webcast today, November 15, 2023 at 8:00 a.m. ET LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ:GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock tran

      11/15/23 7:00:00 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Healthpeak Properties Reports Third Quarter 2023 Results and Declares Quarterly Cash Dividend on Common Stock

      Healthpeak Properties, Inc. (NYSE:PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the third quarter ended September 30, 2023. THIRD QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS – Net income of $0.12 per share, Nareit FFO of $0.46 per share, FFO as Adjusted of $0.45 per share, AFFO of $0.40 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 6.0% – Third quarter new and renewal lease executions totaled 2.3 million square feet: • Outpatient Medical new and renewal lease executions totaled 2.1 million square feet, an all-time quarterly high, including a 1.3 millio

      10/30/23 7:00:00 AM ET
      $GRPH
      $PEAK
      Medicinal Chemicals and Botanical Products
      Health Care
      Real Estate Investment Trusts
      Real Estate

    $GRPH
    SEC Filings

    See more
    • SEC Form 424B3 filed by Graphite Bio Inc.

      424B3 - LENZ Therapeutics, Inc. (0001815776) (Filer)

      5/9/24 4:18:06 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Graphite Bio Inc.

      10-Q - LENZ Therapeutics, Inc. (0001815776) (Filer)

      5/8/24 5:11:18 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)

      5/8/24 4:05:56 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    $GRPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mccollum James W bought $501,093 worth of shares (31,332 units at $15.99) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      5/14/24 5:29:43 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • New insider Alpha Wave Ventures Gp, Ltd claimed ownership of 3,612,211 shares (SEC Form 3)

      3 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/28/24 4:31:03 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ra Capital Management, L.P. was granted 3,245,785 shares, bought $14,023,561 worth of shares (933,038 units at $15.03) and bought $976,514 worth of Common Stockj (64,971 units at $15.03) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/25/24 8:48:33 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    $GRPH
    Financials

    Live finance-specific insights

    See more
    • Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics

      Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger Graphite Bio, Inc. (NASDAQ:GRPH) ("Graphite" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Lenz Therapeutics, Inc. ("LENZ") pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.03 per share of Graphite's common stock, will be payable in cash to the stockholders of record as of March 18, 2024. The exact amount of the special dividend will be calculated afte

      3/8/24 5:00:00 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • LENZ Therapeutics and Graphite Bio Announce Merger Agreement

      - Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics' lead assets for the treatment of presbyopia - Combined company expected to have approximately $225 million of cash or cash equivalents at close, including $53.5 million from a concurrent PIPE financing - Companies to host joint webcast today, November 15, 2023 at 8:00 a.m. ET LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ:GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock tran

      11/15/23 7:00:00 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Healthpeak Properties Reports Third Quarter 2023 Results and Declares Quarterly Cash Dividend on Common Stock

      Healthpeak Properties, Inc. (NYSE:PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the third quarter ended September 30, 2023. THIRD QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS – Net income of $0.12 per share, Nareit FFO of $0.46 per share, FFO as Adjusted of $0.45 per share, AFFO of $0.40 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 6.0% – Third quarter new and renewal lease executions totaled 2.3 million square feet: • Outpatient Medical new and renewal lease executions totaled 2.1 million square feet, an all-time quarterly high, including a 1.3 millio

      10/30/23 7:00:00 AM ET
      $GRPH
      $PEAK
      Medicinal Chemicals and Botanical Products
      Health Care
      Real Estate Investment Trusts
      Real Estate

    $GRPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mccollum James W bought $501,093 worth of shares (31,332 units at $15.99) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      5/14/24 5:29:43 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ra Capital Management, L.P. was granted 3,245,785 shares, bought $14,023,561 worth of shares (933,038 units at $15.03) and bought $976,514 worth of Common Stockj (64,971 units at $15.03) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/25/24 8:48:33 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    $GRPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Graphite Bio Appoints Alethia Young as Chief Financial Officer

      Graphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the appointment of Alethia Young as chief financial officer. Ms. Young joins Graphite Bio from Cantor Fitzgerald, where she served as senior biotech analyst and head of research, managing the equity research department covering small-cap, mid-cap and large-cap biotechnology companies. In this newly created position, Ms. Young will oversee the company's finance, investor relations and corporate communications functions, and will play a key role in overall corporate strategy. "On behalf of the e

      3/2/22 8:00:00 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    $GRPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Graphite Bio Inc. (Amendment)

      SC 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

      4/8/24 2:46:09 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Graphite Bio Inc.

      SC 13G - LENZ Therapeutics, Inc. (0001815776) (Subject)

      3/28/24 4:30:24 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Graphite Bio Inc.

      SC 13D - LENZ Therapeutics, Inc. (0001815776) (Subject)

      3/28/24 4:16:06 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care